PRA International Achieves Highest Accreditation in Medidata CRO Program
New York, NY and Raleigh, NC
Medidata Solutions,, a global provider of hosted clinical development solutions, announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers. The highest achievable tier in the program, Rave Accredited Plus enables PRA to independently offer its customers a full suite of services around the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform, including end-user training, study build, reporting, outputs, integrations and migrations.
A full-service contract research organization (CRO) with more than 3,100 global employees, PRA International conducts clinical trials in more than 75 countries across six continents and provides services through all phases of clinical development. PRA has extensive experience delivering more than 150 EDC trials across six continents and started working with Medidata in 2000 as one of Medidata’s first CRO go-to-market partners. PRA formalized its partnership through the ASPire to Win program in 2008. This latest accreditation brings PRA to 18 fully trained Rave database developers, helping PRA’s ability to support its clients’ EDC needs around the globe.
“Achieving the Rave Accredited Plus status in the Medidata partner program gives us a substantial number of staff members with Rave expertise and allows us to deliver key EDC service offerings to our sponsors,” said Mary Mattes, Executive Director of Data Management at PRA International.
“PRA’s accreditation and the expansion of its Medidata Rave-trained team will enable PRA to respond to sponsor demand for Medidata Rave and continue to grow its global customer base,” said Graham Bunn, Vice President of Global CRO Partnerships at Medidata Solutions.
Medidata first announced ASPire to Win in April 2005 as a partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include more than 20 partners, ranging from smaller clinical consultancies to large, global CROs. The program offers the choice of four enablement levels – Rave Aware, Rave Ready, Rave Accredited and Rave Accredited Plus.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
